1. Home
  2. PZG vs ALXO Comparison

PZG vs ALXO Comparison

Compare PZG & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paramount Gold Nevada Corp.

PZG

Paramount Gold Nevada Corp.

HOLD

Current Price

$1.12

Market Cap

94.8M

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.36

Market Cap

79.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PZG
ALXO
Founded
1992
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.8M
79.7M
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
PZG
ALXO
Price
$1.12
$1.36
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$3.30
AVG Volume (30 Days)
687.6K
350.9K
Earning Date
11-14-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.40
52 Week High
$1.41
$2.27

Technical Indicators

Market Signals
Indicator
PZG
ALXO
Relative Strength Index (RSI) 44.69 47.97
Support Level $1.18 $1.29
Resistance Level $1.26 $1.56
Average True Range (ATR) 0.08 0.15
MACD -0.01 -0.01
Stochastic Oscillator 24.00 39.82

Price Performance

Historical Comparison
PZG
ALXO

About PZG Paramount Gold Nevada Corp.

Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold, frost project, other non-material, and others.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: